LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2019, the platform in Europe devoted entirely to the development and use of the immunotherapies against cancer, will take place from 11-14 December in Geneva, Switzerland, and will attract around one thousand participants from all over the world.
The event provides a comprehensive overview of this fast-moving field, from recent advances to those in the pipeline and is addressed to basic, translational and clinical researchers, immunologists, oncology clinicians.
The Congress programme features numerous thought-provoking sessions about hot topics in the field of immuno-oncology, such as:
- Artificial intelligence (AI) meets immune-oncology (Friday, 13 December at 14:30 CET)
- Reducing costs by decreasing either dose or frequency of dosing (Saturday, 14 December at 11:00 CET)
- Status of CAR T-cells for cancer- Keynote lecture by Carl H. June (Wednesday, 11 December at 13:00 CET)
- Mechanisms of immunotherapy efficacy versus resistance - Keynote lecture by by Thomas Gajewski, winner of the 2019 ESMO Award for Immuno-Oncology (Thursday, 12 December at 14:20).
Updated results will be presented for the following studies:
- LBA1 - Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
- LBA2 - First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
- LBA3 - Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 Part 2 final analysis
- LBA4 - Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042
- LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Other key aspects will be dealt with and discussed by expert panellists, including:
- Integrate Tumour Mutational Burden into daily practice, the way toward standardization
- Use of steroids and corticosteroids in immunotherapy
- Immunotherapy as first-line treatment across a range of tumour types
- Combination therapy in solid tumours
ESMO welcomes members of the press interested in reporting on cancer. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
ESMO Press Office
Official Congress Hashtag: #ESMOImmuno19